Immutep Ltd has released a press release.
Excellent initial Overall Survival Benefit in 1st line NSCLC
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Immutep
- FDA supportive of Efti registrational trial in lung cancer
- Approval to start Efti & Bavencio trial in urothelial cancer
- Immutep to announce new TACTI-002 data at ASCO 2023
- Response to ASX Aware Query
- Initiation of Phase 2 Trial for Efti in Soft Tissue Sarcoma
Later from Immutep
- Promising New Data in 1st line NSCLC from INSIGHT-003 Trial
- 1st patient dosed in AIPAC-003 ph2/3 breast cancer trial
- Publication of Abstracts for ASCO 2023 Annual Meeting
- Charles River Laboratories to run IMP761 Toxicology Study
- A$80 million fully underwritten equity raising
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep